this is not my field so I am interested in your views here.

Oxford Bio claim :

"ProSavin delivers to the patient’s brain three genes required to convert cells that normally do not produce dopamine into cells that do, thereby replacing the dopamine synthesising cells lost during the course of the disease. ProSavin is based on a novel LentiVector system carrying the genes AADC (aromatic amino acid dopa decarboxylase), TH (tyrosine hydroxylase) and CH1 (GTP-cyclohydrolase 1). These genes are able to reprogramme transduced cells to manufacture and secrete dopamine".

Accepting your point re. lack of proof of the claim of efficacy vs L-dopa, I am interested in your views as to the potential of this product.

I am also interested in why Oxford and others would view this as worth the cost of testing.

Please try to keep the explanation simple, I am a mere techie and the world of gene therapy can easily go over my head.

Thanks for your help,
Aftermathman.